Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reversed with neostigmine versus sugammadex

Minerva Anestesiologica

Volumn 82, Issue 7, 2016, Pages 735-742

  Martinez Ubieto, Javier ^a   Ortega Lucea, Sonia ^a   Pascual Bellosta, Ana ^a   Arazo Iglesias, Ivan ^a   Gilbona, Jesús ^a   Jimenez Bernardó, Teresa ^a   Muñoz Rodriguez, Luis ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Neuromuscular block postoperative complications sugammadex

Indexed keywords

CISATRACURIUM; NEOSTIGMINE; ROCURONIUM; SUGAMMADEX; ATRACURIUM BESILATE; CHOLINESTERASE INHIBITOR; GAMMA CYCLODEXTRIN DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT;

ARTICLE; ATELECTASIS; COHORT ANALYSIS; GENERAL ANESTHESIA; GENERAL MEDICAL DEVICE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NEUROMUSCULAR BLOCKING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PNEUMONIA; POSTANESTHESIA CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; POSTOPERATIVE RESIDUAL CURARIZATION; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; ANALOGS AND DERIVATIVES; ANESTHETIC RECOVERY; BREATHING DISORDER; CHEMICALLY INDUCED; DELAYED EMERGENCE FROM ANESTHESIA; NEUROMUSCULAR MONITORING;

ANESTHESIA RECOVERY PERIOD; ATRACURIUM; CHOLINESTERASE INHIBITORS; DELAYED EMERGENCE FROM ANESTHESIA; GAMMA-CYCLODEXTRINS; HUMANS; NEOSTIGMINE; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR MONITORING; NEUROMUSCULAR NONDEPOLARIZING AGENTS; PROSPECTIVE STUDIES; RESPIRATION DISORDERS;

EID: 84979955377     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Murphy G, Szokol J, Marymont J, Greenberg S, Avram M, Vender J. Residual Neuromuscular Blockade and Critical Respiratory Events in the Postanesthesia Care Unit. Anesth Analg 2008;107:130-7.
2. Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarization in the recovery room after vecuronium: A meta- Analysis. Br J Anaesth 2007;98:302-16.
3. Hines R, Barash PG, Watrous G, O'Connor T. Complications occurring in the postanesthesia care unit: A survery. Anesth Analg. 1992;74:503-9.
4. Pedersen T, Viby-Mogensen J, Ringsted C. Anaesthetic practice and postoperative pulmonary complications. Acta Anaesthesiol Scand. 1992;36:812-8.
5. Rose DK, Cohen MM, Wigglesworth DF, DeBoer DP. Critical respiratory events in the postanesthesia care unit. Patient, surgical, and anesthetic factors. Anesthesiology. 1994;81:410-8.
6. Butterly A, Bittner EA, George E, Sandberg S, Eikermann M, Schmidt U. Postoperative residual curarization from intermediate- Acting neuromuscular blocking agents delays recovery room discharge. Br J Anaesth 2010; 105:304-9.
7. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 2003;98:1042-8.
8. Baillard C, Gehan G, Reboul-Marty J, Larmignat P, Samana CM, Cupa M. Residual curarization in the recovery room after vecuronium. Br J Anaesth 2000;84:394-5.
9. McCaul C, Tobin E, Boylan JF, McShane AJ. Atracurium is associated with postoperative residual curarization. Br J Anaesth 2012;89:766-9.
10. Viby-Mogensen J, Engbaek J, Eriksson LI, Gramstad L, Jensen E, Jensen FS, et al. Good clinical reseach practice (GCRP) in pharmacodynamics studies of neuromuscular blocking agents. Acta Anaesthesiol Scand 1996; 40:59- 74.
11. Maybauer DM, Geldner G, Blobner M, Pühringer F, Hofmockel R, Rex C, et al. Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium. Anaesthesia 2007;62:12-7.
12. Baillard C, Clech C, Catineau J, Salhi F, Gehan G, Cupa M, et al. Postoperative residual neuromuscular block: A survey of management. Br J Anaesth 2005;95:622-5.
13. Hayes AH, Mirakhur RK, Breslin DS, Reid JE, Mc- Court KC. Postoperative residual block after intermediate- Acting neuromuscular blocking drugs. Anaesthesia 2001;56:312-8.
14. Yip P, Hannam A, Cameron A, Campbell D. Incidence of residual neuromuscular blockade in a post- Anaesthetic care unit. Anaesth Intensive Care 2010;38:91-5.
15. Murphy GS, Szokol JW, Marymonth JH, Greenberg SB, Avram MJ, Vender JS, et al. Intraoperative acceleromyographic monitoring reduces the risk residual neuromuscular blockade and adverse respiratory events in the postaesthesia care unit. Anesthesiology 2008;109:389-98.
16. Arbous SM, Meursing A, Van Kleef J, De Lange JJ, Spoormans HH, Touw P, et al. Impact of Anesthesia management characteristics on severe morbidity and mortality. Anesthesiology 2005;102:257-68.
17. Cammu G, Smet V, De Jongh K, Vandeput D. A prospective, observational study comparing postoperative residual curarization and early adverse respiratory events in patients reversed with neostigmine or sugammadex or alter apparent spontaneous recovery. Anaesth Intensive Care 2012;40:999-1006.
18. Kopman AF, Znk LM, Ng J, Neumann GG. Antagonism of cisatracurium and rocuronium block at tactile train-oftour count of 2: should quantitative assessment of neuromuscular function be mandatory? Anesth Analg 2004; 98:102-6.
19. De Boer HD, Van Egmond J, Van de Pol F, Bom A, Booijj LH. Sugammadex a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. Br J Anaesth 2006;96:473-9.
20. White PF, Tufanogullari B, Sacan O, Pavlin EG, Viegas OJ, Minkowitz HS, et al. The effect neuromuscular residual blockade on the speed of reversal with sugammadex. Anesth Analg 2009;108:846-51.
21. Berg H, Roed J, Viby-Mogensen J, Mortensen CR, Eng- baek J, Skovgaard LT, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomized, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997;41:1095-103.
22. Bissinger U, Schikmek F, Lenz G. Postoperative residual paralysis and respiratory status: A comparative study of pancuronium and vecuronium. Physiol Res 2000;49:455-62.
23. Norton M, Xara D, Parente D, Barbosa M, Abelha FJ. Residual neuromuscular block as a a risk factor for critical respiratory events in the postanesthesia care unit. Rev Esp Anestesiol Reanim 2013;60:190-6.
24. Ledowsky T, Hillyard S, O'Dea B, Archer R, Vilas-Boas F, Kyle B. Introduction of sugammadex as reversal agent: Impact on the incidence of residual neuromuscular blockade and postoperative patient outcome. Indian J Anaesth 2013;57:46-51.
25. Della Rocca G, Di Marco P, Beretta L, De Gaudio AR, Ori C, Mastronardi P. Do we need to use sugammadex at the end of a general anesthesia to reverse the action of neuromuscular bloking agents? Position paper on Sugammadex use. Minerva Anestesiol 2013;79:661-6.
26. Murphy G, Brull S. Lessons unlearned. Part I: Definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg 2010;111:120-8.